07:00 , Sep 9, 2013 |  BioCentury  |  Product Development

Checkpoint complementarity

The acquisition of Amplimmune Inc. adds a new set of immune checkpoint targets to MedImmune LLC's cancer portfolio, giving it more potential combinations to test in cancer. The AstraZeneca plc unit now has four disclosed checkpoint...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Amplimmune, Daiichi Sankyo deal

Amplimmune granted Daiichi an exclusive option to license worldwide rights to develop and commercialize Amplimmune's AMP-110. The option is exercisable through the completion of a proof-of-concept (POC) Phase II trial of the product, a...
01:24 , Jan 9, 2013 |  BC Extra  |  Company News

Amplimmune grants Daiichi option for autoimmune product AMP-110

Amplimmune Inc. (Rockville, Md.) granted Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) an exclusive option to license worldwide rights to develop and commercialize Amplimmune's AMP-110. The option is exercisable through the completion of a proof-of-concept (POC)...
07:00 , Aug 9, 2010 |  BioCentury  |  Finance

Amplified Opportunity

Amplimmune Inc. has made the most of an initial $20 million round of financing, as the company has made progress with a pair of preclinical fusion proteins, the more advanced of which was snapped up...
07:00 , Aug 9, 2010 |  BioCentury  |  Finance

Moving on

It is not often that the evolution of a biotech company follows the script, but Movetis N.V. (Euronext: MOVE) has done just that. Since being spun out from Johnson & Johnson (NYSE:JNJ) three-plus years ago,...
08:00 , Nov 12, 2009 |  BC Innovations  |  Cover Story

Restoring immunosuppression in RA

Researchers at The Johns Hopkins University School of Medicine have identified a way to dial down excessive activation of T cells in rheumatoid arthritis and potentially other autoimmune diseases.1Amplimmune Inc. has in-licensed the IP and...
08:00 , Nov 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) ...
07:00 , Aug 31, 2009 |  BC Week In Review  |  Company News

Amplimmune, American National Multiple Sclerosis Society deal

The society's not-for-profit technology transfer subsidiary Fast Forward LLC will provide $500,000 in funding for preclinical development of Amplimmune's AMP-110 to prevent abnormal immune responses associated with multiple sclerosis (MS) and other autoimmune diseases....
07:00 , Jun 15, 2009 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Amplimmune Inc. Rockville, Md. Technology: Fusion protein of B7-DC and the Fc-portion of IgG Disease focus: Cancer, autoimmune Clinical status: Preclinical Founded: 2007 by Lieping Chen, Drew Pardoll, Elizabeth Jaffee, Andrea Cox, Charles Drake and Jonathan Powell University collaborators: Johns Hopkins...
07:00 , Jun 15, 2009 |  BioCentury  |  Emerging Company Profile

Amplimmune: Blocking Immune Evasion

Amplimmune Inc. is working on circumventing one of the mechanisms used by cancer and infected cells to evade the immune system. By preventing receptors from binding with ligands that disable T cell activation, the company...